About Us
Arbele’s mission is to create more effective treatments for GI cancers
We are a clinical stage biotechnology company with our core proprietary technology platform centered on immunotherapy – TriAx Multispecific biologics as well as artificial-immunosurveillance AI-CAR technology for the treatment of gastrointestinal cancers.
Our main focus is on our proprietary biomarker, Cadherin-17 (CDH17), a highly specific target for GI cancers.
John Luk, DMedSc, EMBA
CEO & Founder
Education and training at the University of Hong Kong, Karolinska (Stockholm) and Harvard (Boston)
Taught as academic professor for 18 years in the US, HK and Singapore
Published >200 papers including NEJM, Cell, Nature Medicine, Nature Genetics
Identified and patented CDH17 at HKU (Global License Arbele)
In 2011, moved to drug industry at senior leader position in Roche China and senior director in Johnson & Johnson Medical China to lead drug discovery and development programs in oncology, immunology and hepatitis
Former honorary professorship at leading institutions in HK, China and Asia; visiting associate professor at Harvard; established strong scientific, clinical and industrial networks globally
Dennis Wong, MD
Chief Medical Officer
Former VP Clinical Development of Sanofi in Asia Pacific
>20 years drug development in big pharma (Genentech, Roche, BMS and Sanofi)
Successful track records in FDA drug filing from FIH to NDA (with 5 BLA filed)
Board certified internal medicine, allergy & immunology
Harvard, UCSF, VCU, Chicago, Tokyo University
Ms Khim Poon
Chief Operating Officer
Previously executive Deputy GM, Citic Bank
Senior positions in Development Bank of Singapore (DBS), Standard Chartered, ANZ, ING and Citi
Bachelor of Economics and Master of Applied Finance
Dr Tony Wong, PhD
Chief Technology Officer
More than 10 years experience in drug development with multinational pharmaceutical companies and biotech startups
Target discovery, lead identification, optimization, Investigational New Drug (IND)-enabling studies and clinical trial designs
PhD (University of Hong Kong)
Jovey Chan, LLB, LLM(CFL)
Chief Legal Officer
HKU Law Graduate
15 years as a lawyer and legal counsel
Specialized practice in legal business, with rich M&A experience in technology & energy fields
Cindy Shek, BA
Co-founder & General Manager
Specialized in public administration
20+ year experience in health care and hospital authority
Co-founding Tiberias Ltd, a HK biotech focusing on oncology drug development
Our Focus
Gastrointestinal Cancers
Gastrointestinal cancers presents a pressing challenge marked by unmet medical needs. Stomach, pancreas, colon, bile duct, and liver cancers collectively bear a significant burden, characterized by their high mortality rates and limited treatment alternatives. The complexity of these malignancies demands a new era of innovative therapeutic interventions that can effectively target the intricate molecular pathways driving tumor growth and progression.
Arbele is steadfast in its mission to bridge this therapeutic gap, pioneering groundbreaking drug development to provide hope and healing to patients grappling with these diseases. Our commitment to advancing scientific understanding and delivering novel solutions underscores our dedication to transforming the landscape of gastrointestinal cancer treatment.
Data from GLOBOCAN 2020; International Agency for Research on Cancer, WHO
Location: Seattle | Hong Kong | Guangzhou | Sydney | Singapore
Copyright©2023 Arbele All Rights Reserved.